Cabaletta Bio (NASDAQ:CABA) was founded in 2017. The company is headquartered in Philadelphia, PA, USA. The company is focused on developing T-cell therapeutics for the treatment of autoimmune diseases. The company collaborates with a number of professional institutions such as the University of Pennsylvania, Children’s Hospital of Philadelphia, and biotechnology company IASO Bio.
Cabaletta Bio announced via press release that it has developed a groundbreaking drug, CABA-201, for the treatment of autoimmunity through fully human chemical active receptors. The company has also extended an agreement with WuXi Advanced Thzerapes to manufacture this new drug, CABA-201. This extension of the agreement facilitates the preparation of CABA-201 for commercial use and enables the treatment of patients in several planned clinical trials. This extension of the CABA-201 collaboration builds on an existing manufacturing agreement to supply MuSK-CAART (a drug for an autoimmune disease affecting neuromuscular junctions) for clinical trials.
President of Cabaletta Bio, Gwendolyn Binder said „For the past two years we have had a successful collaboration with WuXi ATU (a biopharmaceutical company that is involved in molecular research, development, manufacturing and biological research, gene therapy testing of medical products) to produce novel cell therapies in a GMP compliant manner. „Based on this collaboration, we have decided to expand our partnership to include WuXi ATU as the manufacturer of our CABA-201 (fully human, chemical, antigen receptor) clinical programs.“ These facts have attracted the attention of multinational investment corporations and private investors to buy shares of Cabaletta Bio (NASDAQ:CABA) in particular, for which they expect strong growth in the share price, for which an average target price of $28.00 per share has been set for the short- to medium-term investment horizon.
